Clinical trial · Observational
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Marker; Structural | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Specimen #1 | Other | — | UNRESOLVED |
| Specimen #2 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer participants
- interventionNames
- Other: Specimen #1
- Other: Specimen #2
- label
- Control Group
- interventionNames
- Other: Specimen #1
- Other: Specimen #2
Primary outcomes (2)
- measure
- Correlation between FABP levels and the development of risk factors for metabolic syndrome and inflammation
- timeFrame
- Baseline
- measure
- To determine the correlation with types of cancer-directed therapy received.
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment * Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy * At least 1-year post-stem cell transplant for malignant condition Exclusion Criteria: 1. Pregnancy at the time of the study 2. Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months 3. Presence of active graft versus host disease 4. Malignancy treated using surgery only 5. Acute relapsed disease or second malignancy 6. Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome) 7. Currently taking systemic steroids and/or immunosuppressant medications 8. Acute illness necessitating hospitalization in the 30 days prior to blood draw 9. Presence of a chronic inflammatory disease EXCEPT obesity 10. Fever, active infection or inflammation, or taking antibiotics at the time of blood draw 11. A diagnosis of Type 2 diabetes or Hypertension treated with medication 12. Currently lipid lowering medications 13. Growth hormone deficiency or hypothalamic dysfunction
References
Publications (0)
Data not yet available